{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:21:17Z","timestamp":1790824877332,"version":"4.1.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,8,14]],"date-time":"2018-08-14T00:00:00Z","timestamp":1534204800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2018.00890","type":"journal-article","created":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T08:12:31Z","timestamp":1534493551000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Assessing the Efficacy of Lopinavir\/Ritonavir-Based Preferred and Alternative Second-Line Regimens in HIV-Infected Patients: A Meta-Analysis of Key Evidence to Support WHO Recommendations"],"prefix":"10.3389","volume":"9","author":[{"given":"Yinqiu","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingbao","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aixin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaokai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1097\/QAD.0000000000000709","article-title":"Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in Africa","volume":"29","author":"Ciaffi","year":"2015","journal-title":"AIDS"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1185\/030079905X65439","article-title":"Comparison of atazanavir with lopinavir\/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial","volume":"21","author":"Cohen","year":"2005","journal-title":"Curr. Med. Res. Opin."},{"key":"B3","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1097\/QAI.0b013e3181bcdac1","article-title":"High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa","volume":"53","author":"Fox","year":"2010","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"B4","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1097\/QAI.0b013e31819c2937","article-title":"A once-daily lopinavir\/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks","volume":"50","author":"Gathe","year":"2009","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"B5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(06)69158-7","article-title":"The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings","volume":"368","author":"Gilks","year":"2006","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"B7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S1473-3099(17)30630-8","article-title":"Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial","volume":"18","author":"Hakim","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/S1473-3099(11)70149-9","article-title":"HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study","volume":"11","author":"Hamers","year":"2011","journal-title":"Lancet Infect. Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1002\/sim.2380","article-title":"A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints","volume":"25","author":"Harbord","year":"2006","journal-title":"Stat. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1758-2652-14-15","article-title":"Driving a decade of change: HIV\/AIDS, patents and access to medicines for all","volume":"14","author":"Hoen","year":"2011","journal-title":"J. Int. AIDS Soc."},{"key":"B12","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/j.1468-1293.2010.00825.x","article-title":"Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline","volume":"11","author":"Hosseinipour","year":"2010","journal-title":"HIV Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med. Res. Methodol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"CD006517","DOI":"10.1002\/14651858.CD006517.pub3","article-title":"Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy","volume":"4","author":"Humphreys","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e433","DOI":"10.1016\/S2352-3018(17)30109-1","article-title":"Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV\/AIDS: a systematic review and network meta-analysis","volume":"4","author":"Kanters","year":"2017","journal-title":"Lancet HIV"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1016\/S2352-3018(17)30149-2","article-title":"Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis","volume":"5","author":"Kelly","year":"2018","journal-title":"Lancet HIV"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e247","DOI":"10.1016\/S2352-3018(16)30011-X","article-title":"Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study","volume":"3","author":"La Rosa","year":"2016","journal-title":"Lancet HIV"},{"key":"B18","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1097\/QAD.0b013e3283360976","article-title":"The high cost of second-line antiretroviral therapy for HIV\/AIDS in South Africa","volume":"24","author":"Long","year":"2010","journal-title":"AIDS"},{"key":"B19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.7326\/0003-4819-155-4-201108160-00358","article-title":"Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda","volume":"155","author":"Mills","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int. J. Surg."},{"key":"B21","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators","volume":"338","author":"Palella","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.4103\/2229-3485.120170","article-title":"Early outcome of second line antiretroviral therapy in treatment-experienced human immunodeficiency virus positive patients","volume":"4","author":"Patel","year":"2013","journal-title":"Perspect. Clin. Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1056\/NEJMoa1311274","article-title":"Assessment of second-line antiretroviral regimens for HIV therapy in Africa","volume":"371","author":"Paton","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1097\/01.mlr.0000228021.89490.2a","article-title":"The lifetime cost of current human immunodeficiency virus care in the United States","volume":"44","author":"Schackman","year":"2006","journal-title":"Med. Care"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/S0140-6736(13)61164-2","article-title":"Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study","volume":"381","author":"SECOND-LINE Study Group Boyd","year":"2013","journal-title":"Lancet"},{"key":"B26","volume-title":"The WHO Public-Health Approach to Antiretroviral Treatment Against HIV in Resource-Limited Settings.","year":"2013"},{"key":"B27","volume-title":"Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach.","year":"2016"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.00890\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T08:12:33Z","timestamp":1534493553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.00890\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,14]]},"references-count":27,"alternative-id":["10.3389\/fphar.2018.00890"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2018.00890","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,14]]},"article-number":"890"}}